Pulmonary metastasis of a papillary thyroid carcinoma and primary lung adenocarcinoma: two coincident carcinomas at the same location
- Liyan Xue†1,
- Zhonghua Luan†1, 2,
- Ying Liu3,
- Shuangmei Zou1,
- Jun Jiang4,
- Ning Wu3, 4,
- Ning Lu1Email author and
- Dongmei Lin1Email author
© Xue et al.; licensee BioMed Central Ltd. 2013
Received: 15 January 2013
Accepted: 10 February 2013
Published: 16 February 2013
Tumor-to-tumor metastasis is a fairly rare phenomenon. The lung cancers are the most common donors, but are exceedingly rare as recipients. Here we report a case of a lung adenocarcinoma acting as the recipient of papillary thyroid carcinoma, with multiple spreading foci of the two cancers in the lung simultaneously. The morphology and immunohistochemisty (Napsin-A, Thyroglobulin) are very important in differential diagnosis of lung primary adenocarcinoma and metastatic papillary thyroid carcinoma.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2069496615891134
KeywordsTumor-to-tumor metastasis Papillary thyroid carcinoma Lung adenocarcinoma Napsin-A Thyroglobulin
Coexistence of two or more primary neoplasms in one patient is not uncommon, however, tumor-to-tumor metastasis is a fairly uncommon but interesting phenomenon. The most frequent recipient is renal clear cell carcinoma, followed by sarcoma, meningioma, and thyroid neoplasm, while the most common donor is lung carcinoma, followed by carcinoma of the breast, gastrointestinal tract, prostate, and thyroid [1, 2]. The lung cancers are the most common donors, but are exceedingly rare as recipients. To date, only 3 cases of lung cancer acting as the recipient of papillary thyroid carcinoma were reported in English-language literature. They were invasive adenocarcinoma, squamous cell carcinoma, and non-mucinous adenocarcinoma in situ, respectively [3–5]. Here we report a case that papillary thyroid carcinoma metastasized into a lung primary invasive adenocarcinoma, with multiple spreading foci of the two cancers in the lung simultaneously.
A 65-year-old Chinese man underwent total thyroidectomy and bilateral neck dissection with 131I treatment after that for papillary thryoid cancer in a local hospital. The papillary thryoid cancer extended to perithyroid soft tissues (pT3) with bilateral neck lymph node metastasis (pN1b). Chest Computed Tomography (CT) scan was not performed that time. Seven months later, a mass in his lung was found without any symptoms in physical examination.
Specimens were fixed in 10% buffered formalin, embedded in paraffin and stained with HE method routinely for histological examination. Immunohistochemical staining was performed using an automated immunostainer (Ventana Benchmark XT; Ventana Medical Systems, Inc, Tucson, AZ). Antibodies against Cytokeratin 19 (CK19), Cytokeratin 7 (CK7), Napsin-A, Thyroglobulin and Thyroid Transcription Factor-1 working solution (CK19 and CK7: Zhong Shan –Golden Bridge Biological Technology Co. Ltd., Beijing, China; Napsin-A and Thyroid Transcription Factor-1: Maxim Biological Techology Co. Ltd., Fuzhou, China; Thyroglobulin: Dako Corp, Carpinteria, CA, USA). Antigen recovery was conducted using moderate heat retrieval according to manufacturer’s recommendation. Slides were incubated with the primary antibody for 30 mininutes at room temperature.
Gross examination showed a tumor in the periphery of the lung, measuring 3.5 × 3.5 × 2.5 cm. The cut section surface of the tumor was hard, grey and fine granular. There were many small grey nodes in the rest lung and pleura, with a diameter of 0.1 cm to 0.3 cm. There were plenty of small nodes on the visceral pleura (Figure 1).
Very few reports of tumor-to-tumor metastasis are present in the English literature. The terms “tumor-to-tumor metastasis” and “collision tumor” have often been confused with one another, and used incorrectly in the literature. Collision tumor is defined as two neighboring neoplasms that invade one another. Tumor-to-tumor metastasis has proved more difficult to be defined, with several proposed similar criteria in order to be classified correctly. The criteria of Campbell et al. to define tumor-to-tumor metastasis are as follows . (1) more than one primary tumor must exist; (2) the recipient tumor is a true benign or malignant neoplasm; (3) the metastatic neoplasm is a true metastasis with established growth in the host tumor, not the result of contiguous growth (collision tumor) or embolization of tumor cells; (4) involvement by metastatic tumors of lymph nodes already involved by lymphoproliferative disease (lymphoreticular malignant tumors) is excluded. According to the literature, renal clear cell carcinoma is the most common tumor recipient of metastasis while lung carcinoma is the most common donor tumor [1, 2, 6]. Tumor-to-tumor metastasis is not as infrequent as previously thought and may be present in up to 15 percent of patients with simultaneous renal clear cell carcinoma and second neoplastic disease . Commonly, the donor tumor is an aggressive malignant tumor. On the other hand, the recipient tumor is usually a low-grade malignancy or benign neoplasm. It is extremely rare that an aggressive malignant tumor as the recipient tumor while a low-grade malignancy as the donor tumor. Only three cases of papillary thyroid carcinoma, a low-grade malignancy, metastasizing to a lung cancer, an aggressive malignant tumor, were reported [3–5]. There were more reports about lung cancer metastasizing to a thyroid tumor [7–10].
The tumor cells (forming the ‘seed’) are hematogenously disseminated in a widespread manner to different anatomic sites, but attain successful growth and propagation only under the favorable local microenvironments of specific organs or the recipient tumors (the ‘soil’). Renal clear cell carcinoma is the most common recipient tumor in tumor-to-tumor metastasis. This might be attributable to its increased vascularity. Biochemical properties of renal cell carcinoma, such as increased cytoplasmic lipid and glycogen of constituent cells, has also been proposed as contributing to this tumor being a favorable site for metastatic growth . The lung is one of the most frequent sites of metastasis for the extrathoracic cancers. However, lung carcinoma is one of the rarest recipients for tumor-to-tumor metastasis. Presence of different vascular structures between normal lung and lung cancer may be the possible reason for the different potential as a site of metastasis. Unlike normal lung, lung cancer doesn’t contain a rich network of small thin-walled blood vessels. The other possible explanation which we considered was that lung cancer is rapidly growing tumor therefore it cannot provide a suitable environment for the acceptance of metastasis. Regarding the reason for the relatively high incidence of lung cancer as a donor in tumor-to-tumor metastasis, the rich vascularity of lung carcinoma in association with the probable shedding of tumor cells during respiratory movement might increase the frequency of invasion into the pulmonary vein and subsequently into the general circulation. The tumor emboli from lung cancer have a better chance to reach all the body organs through the left-sided cardiac output than cancers of the other organs.
It is still unexplained whether tumor-to-tumor metastasis is merely of a chance occurrence or is a selective growth within the recipient tumor. In our case, a lung mass with metastatic papillary thyroid carcinoma was the first metastatic focus discovered during the post-operative follow-up of this patient. Our case showed that the metastatic papillary thyroid adenocarcinoma foci were not limited to the primary lung adenocarcinoma and multiple microscopic foci of thyroid papillary foci were observed in the surrounding normal lung tissue. Multi foci of metastases can also be seen both within the lung cancer and in the background lung tissue in the 3 reported cases of a lung cancer acting as the recipient of a donor of papillary thyroid carcinoma [3–5]. In addition, multiple spreading small lung adenocarcinoma can also be seen in the background lung tissue in our present case while the 3 reported cases didn’t show this. Papillary thyroid carcinoma is a slowly growing tumor. Disease-specific survival with distant metastases at 5 and 10 years was reported to be 65 and 45%, respectively . The metastatic foci of papillary thyroid carcinoma had probably already been there before lung primary adenocarcinoma occurred, and the metastases to lung cancer had occurred by chance.
The presence of a lung mass in a patient with a prior cancer can represent a clinically and/or pathologically diagnostic challenge. Some of these lung masses represent primary processes rather than metastatic deposits. The diagnosis of metastatic carcinoma to the lung by core biopsy, frozen section, and permanent sections can be easily misinterpreted as a primary tumor. The possibility of metastatic papillary thyroid carcinoma should always be considered when two different cell populations are identified, and specifically, one should be aware of in the presence of papillary component in a lung carcinoma. The diagnosis of metastatic papillary thyroid carcinoma mainly depends on the morphology of the nucleus and immunohistochemical expression. The papillary thyroid carcinoma is composed of cells with ground glass nuclei in the cells and colloid in the thyroid follicles, which are the important characteristics different from other carcinomas. Lepdic or adenocarcinoma in situ components in the surgical specimens can also help to differentiate primary lung adenocarinoma from other carcinomas. Thyroid Transcription Factor-1 is one of the immunohistochemical markers most commonly used to assist in the differential diagnosis of carcinomas of the lung and thyroid from other carcinomas. But it cannot differentiate between lung carcinoma and thyroid carcinoma. CK19, galectin-3 (Gal-3) and Hector Battifora mesothelial-1 (HBME-1) have been studied to distinguish between malignant and benign lesions of the thyroid gland. The diagnostic efficiency of CK19 for papillary thyroid carcinoma was slightly better than that of Gal-3 and HBME-1. The utilization of these markers combined with morphologic evaluation may be helpful in the differential diagnosis of papillary thyroid carcinoma and benign lesions [13, 14]. But they cannot distinguish metastatic papillary thyroid carcinoma from lung adenocarcinoma. Thyroglobulin is an antibody specially expressed in normal thyroid and thyroid carcinoma, which we can use in the differential diagnosis of lung carcinoma and thyroid carcinoma. Napsin A is an aspartic proteinase involved in the maturation of surfactant protein B. It is detected in the cytoplasm of type 2 pneumocytes and alveolar macrophages and is a putative marker for lung adenocarcinomas. It can also help to differentiate lung adenocarcinoma from metastatic papillary thyroid carcinoma . Recently, microarray based gene expression profiling has found increasing use, particularly in the most difficult cases. Gene expression profiling provides correct primary site identification in a higher percentage, of metastatic cases than immnunohistochemistry-guided methods (90% vs. 64%), and uses less tissue . In our present case, the morphology and immunohistochemical expression of the two components were typical. It was a rare case, but not difficult for pathologist, so gene expression profiling is not necessary.
In summary, when there is a tumor in the lung of a patient with papillary thyroid carcinoma history, tumor-to-tumor metastasis should be considered. Such a tumor-to-tumor metastasis should be differentiated from primary mixed adenocarcinoma, which is composed of papillary adenocarcinoma and other subtypes of adenocarcinoma of lung. Tumor-to-tumor metastasis may become more frequent because of the improving prognosis and survival of patients with malignancies. Awareness about this phenomenon of tumor-to-tumor metastasis, careful examination of morphology and proper immunohistochemical staining such as Thyroglobulin and Napsin A are important for correct diagnosis and appropriate therapy.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
This study was supported by National Natural Science Foundation of China (no. 81272414 and no. 81272308) and the Beijing Hope Run Special Fund (No. LC2012B26).
- Petraki C, Vaslamatzis M, Argyrakos T, Petraki K, Strataki M, Alexopoulos C, Sotsiou F: Tumor to tumor metastasis: report of two cases and review of the literature. Int J Surg Pathol. 2003, 11: 127-135. 10.1177/106689690301100214.View ArticlePubMedGoogle Scholar
- Campbell LV, Gilbert E, Chamberlain CR, Watne AL: Metastases of cancer to cancer. Cancer. 1968, 22: 635-643. 10.1002/1097-0142(196809)22:3<635::AID-CNCR2820220320>3.0.CO;2-O.View ArticlePubMedGoogle Scholar
- Roscoe KJ, Raja S, Tronic B, Dou Y: Single F-18 fluorodeoxyglucose positron emission tomography hypermetabolic focus containing metastatic papillary thyroid cancer within a primary scarring adenocarcinoma lung cancer. Clin Nucl Med. 2006, 31: 359-360. 10.1097/01.rlu.0000219081.67943.90.View ArticlePubMedGoogle Scholar
- Nonomura A, Mizukami Y, Shimizu J, Watanabe Y, Kamimura R, Takashima T: Two patients with metastasis of cancer to other neoplasm: a thyroid carcinoma metastatic to a lung carcinoma and a gastric carcinoma metastatic to a thyroid adenoma. Endocr Pathol. 1994, 5: 233-239. 10.1007/BF02921492.View ArticleGoogle Scholar
- Kim KM, Kim YN, Chu HH, Jin HY, Kim MH, Chung MJ: Papillary carcinoma of thyroid metastatic to adenocarcinoma in situ of lung: report of an unusual case. Korean J Pathol. 2012, 46: 282-286. 10.4132/KoreanJPathol.2012.46.3.282.PubMed CentralView ArticlePubMedGoogle Scholar
- Sella A, Ro JY: Renal cell cancer: best recipient of tumor-to-tumor metastasis. Urology. 1987, 30: 35-38. 10.1016/0090-4295(87)90568-1.View ArticlePubMedGoogle Scholar
- Hashimoto K, Yamamoto H, Nakano T, Oyama M, Shiratsuchi H, Nakashima T, Tamiya S, Komune S, Oda Y: Tumor-to-tumor metastasis: lung adenocarcinoma metastasizing to a follicular variant of papillary thyroid carcinoma. Pathol Int. 2011, 61: 435-441. 10.1111/j.1440-1827.2011.02679.x.View ArticlePubMedGoogle Scholar
- Baloch ZW, LiVolsi VA: Tumor-to-tumor metastasis to follicular variant of papillary carcinoma of thyroid. Arch Pathol Lab Med. 1999, 123: 703-706.PubMedGoogle Scholar
- Kameyama K, Kamio N, Okita H, Hata J: Metastatic carcinoma in follicular adenoma of the thyroid gland. Pathol Res Pract. 2000, 196: 333-336. 10.1016/S0344-0338(00)80065-5. discussion 337–338View ArticlePubMedGoogle Scholar
- Stevens TM, Richards AT, Bewtra C, Sharma P: Tumors metastatic to thyroid neoplasms: a case report and review of the literature. Patholog Res Int. 2011, 2011: 238693-PubMed CentralPubMedGoogle Scholar
- Ortega P, Li IY, Shimkin M: Metastasis of neoplasms to other neoplasms. Ann West Med Surg. 1951, 5: 601-609.PubMedGoogle Scholar
- Sugitani I, Fujimoto Y, Yamamoto N: Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery. 2008, 143: 35-42. 10.1016/j.surg.2007.06.011.View ArticlePubMedGoogle Scholar
- Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A, da Silva Pinhal MA: Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol. 2012, 7: 97-10.1186/1746-1596-7-97.PubMed CentralView ArticlePubMedGoogle Scholar
- Song Q, Wang D, Lou Y, Li C, Fang C, He X, Li J: Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol. 2011, 6: 126-10.1186/1746-1596-6-126.PubMed CentralView ArticlePubMedGoogle Scholar
- Bishop JA, Sharma R, Illei PB: Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010, 41: 20-25. 10.1016/j.humpath.2009.06.014.View ArticlePubMedGoogle Scholar
- Kulkarni A, Pillai R, Ezekiel AM, Henner WD, Handorf CR: Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer. Diagn Pathol. 2012, 7: 110-10.1186/1746-1596-7-110.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.